

ISSN Print: 2664-8350
ISSN Online: 2664-8369
Impact Factor: RJIF 6.02
IJPN 2026; 8(1): 25-39
www.pediatricsjournal.net
Received: 17-10-2025
Accepted: 19-11-2025

Sahar Hassan
Department of Pediatric Nursing, Faculty of Nursing, University of Babylon, Babylon, Iraq

Corresponding Author:
Sahar Hassan
Department of Pediatric Nursing, Faculty of Nursing, University of Babylon, Babylon, Iraq

A comprehensive narrative review of the comorbidity of autism spectrum disorder and ADHD in children

Sahar Hassan

DOI: https://www.doi.org/10.33545/26648350.2026.v8.i1a.181

Abstract
Co-occurring Autism Spectrum Disorder (ASD) and Attention-Deficit/Hyperactivity Disorder (ADHD) is currently the most common and difficult-to-manage dual diagnosis in child neuropsychiatric disorders. For many decades, these two conditions remained in separate diagnostic compartments according to conventional psychiatric nomenclature. With their unified recognition in DSM-5 in 2013, this recognition has completely transformed clinical approaches and research paradigms in this area. This narrative review is intended to be an exhaustive and systematic synthesis of the current scientific reality of ASD and ADHD in children. Its scope would include the regression of the available epidemiological studies in the field, analyzing their common and differing pathoetiological architectures in genetics, neuroscience, and neuromechanisms, while characterizing their own distinct phenotypes combined in this particular dual diagnosis setting. Since this dual diagnosis has explosive effects in terms of intellectual and adaptive performance in children, most of our discussion would address this aspect in depth. The vast implications in terms of academic, social, and adaptive functionalities, as well as outcomes, have been examined in depth. Finally, we have been able to identify areas of ongoing controversy, knowledge gaps, and future research areas including the need for trans-diagnostic approaches, studies of treatment sequencing, and approaches from a lifespan perspective. This review of existing literature brings closure to the immense body of knowledge available for the benefit of the reader to comprehend that the understanding of children with ASD and ADHD is more than just managing comorbidities.

Keywords: Autism Spectrum Disorder, Attention Deficit/Hyperactivity Disorder, Comorbidity, Co-Occurrence, Neurodevelopment, Children, Diagnosis, Pharmacotherapy, Behavioral

1. Introduction
The history of autism spectrum disorder and attention-deficit hyperactivity disorder in these manuals parallels a broader shift in psychiatric thinking from strict exclusivist categories to a recognition of dimensional and overlapping phenomena. For most of the latter 20th century, for instance, the DSM-III-R and DSM-IV strictly excluded co-diagnosis with ASD (previously referred to as Autistic Disorder and Asperger's Disorder). The existence of ADHD would be understood either to be subsumed by ASD or indicative of a separate, but necessarily separate, condition [1, 2]. While essentially an artifact of history and tradition rather than a reflection in any direct way of reality, this strict line was a major area of clinical neglect. Throughout these decades, professionals and families alike described children with significant manifestations on both sides. The strictly required choice was bound to result in disjointed conceptualizations [3].

For the first time, simultaneous diagnosis of ASD and ADHD was made possible by the DSM-5, marking a significant paradigm change. Impressive epidemiological data showing high rates of co-occurrence, significant twin studies showing shared genetic vulnerabilities, and a growing understanding that comorbidity was the rule rather than the exception in child psychiatry were all contributing factors to this shift [4]. Formal recognition has spurred an exponential growth in study from a position of relatively little knowledge about two purportedly distinct illnesses, strengthening our understanding along a route of overlapping neurodevelopmental processes [5].

Terminology is also up for debate. 'Comorbidity, ' which refers to the co-occurrence of two disease entities, may not adequately reflect the common underlying factors. There is also the use of terms such as 'co-occurrence, ' 'co-existence, ' or even 'complex ADHD/ASD' instead.

ESSENCE is another important contribution to the discussion on the topic. ESSENCE is the acronym that stands for Early Symptomatic Syndromes Eliciting Neurodevelopmental Clinical Examinations. This is the framework developed by Gulberg [6, 7].

This narrative review intends to embark on a comprehensive and meticulous analysis of the co-morbidity of ASD and ADHD in children. We propose to cover the journey from etiology and neurobiology, through diagnosis, comprehensive management strategies, and ultimately, prognosis. By incorporating various perspectives of knowledge from genetics, neurobiology, psychology, and psychiatry, our ambition is to provide a holistic and exhaustive resource guide that aims to forge new paths in future research on this crucial crossroad in the arena of child development.

2. Epidemiology: Prevalence, Correlates, and Demographic Patterns

Being accurate about epidemiological information is essential to grasping the extent of this problem. There is enormous divergence regarding the prevalence rates of comorbidity involving ASD and ADHD, according to research design variables. These include population versus clinic-referred samples, use of DSM-IV versus DSM-5 criteria, research tools (parent-report surveys versus standardized diagnostic tools), as well as subject age and intelligence level.

Table 1: Epidemiological Studies of ASD and ADHD Comorbidity [7-12].

Study (Year)	Sample	Key Findings	Prevalence Estimates
Lai *et al*. (2019) - Meta-Analysis	112 studies (n=96, 423)	Pooled prevalence of ADHD in ASD. Higher in clinical vs. population samples.	In ASD: 28.2% (95% CI 25.2-31.5%)
Rong *et al*. (2021) - Meta-Analysis	63 studies (n=92, 642)	Comprehensive meta-analysis of ADHD prevalence in ASD.	In ASD: 38.5% (95% CI 36.2-40.8)
Joshi *et al*. (2017)	Psychiatrically referred youth	Compared symptom profiles. High rates of comorbidity in clinical settings.	ADHD in ASD: ~70% ASD in ADHD: ~30%
Grzadzinski *et al*. (2016)	Children with ADHD	Examined ASD symptoms using ADOS and parent report.	ASD in ADHD: 18-26% (depending on measure)
Stevens *et al*. (2016)	National survey data (US)	Analyzed comorbidity using parent-reported diagnoses.	ADHD in ASD: 39.5% ASD in ADHD: 13.5%

Key Epidemiological Insights

1. **High Prevalence:** It is certainly one of the most frequent comorbid conditions found in child psychiatric clinics." Even conservative estimates tell us that 30-40% of children diagnosed with ASD exhibit significant symptoms of ADHD, and 20-30% with ADHD exhibit sufficient symptoms to meet criteria for ASD. However, these figures are significantly higher in referred samples [13].
2. **Bidirectional Risk:** Two-way relationship. The presence of one significantly raises the risk of the development of the other, suggesting that one is not a subtype or complication of the other [13].
3. **Impact of Intellectual Ability (ID):** The incidence of ADHD co-occurrences remains significantly high in people with ASD and intellectual disability (ID). Research suggests that the prevalence rate for symptoms of ADHD can be above 80% in children with ASD and moderate to severe intellectual disability. Nonetheless, making a proper diagnosis for ADHD in the setting of intellectual disability can be challenging in distinguishing from cognitive impulsivity and overactivity [13].
4. **Gender Distribution:** Both ASD and ADHD display a higher prevalence among males than females, the gender ratio being 4:1 for the first condition and 2-3:1 for the latter. Interestingly enough, the gender imbalance is maintained for the jointly affected individuals. Nevertheless, paradoxically enough, the female gender seems to present a higher likelihood to be affected by ADHD among children diagnosed with the first condition [13].
5. **Age and Developmental Course:** Symptoms of both disorders typically begin to emerge when children are young. Hyperactivity, as well as impulsivity, could reach its peak intensity during the early school years, although inattention could persist. In ASD, the Pressures involved will likely increase as children mature, possibly highlighting difficulties. There will be an apparent shift or change in symptoms as executive dysfunction becomes prominent in adolescence [13].
6. **Associated Comorbidities:** The existence of ASD+ADHD melodramatically intensifications the danger for supplementary psychiatric circumstances, fashioning a multifaceted "multi-comorbid" silhouette. Conjoint connotations comprise: [14, 15].

- **Anxiety Disorders:** Specifically including Generalized anxiety disorder; Social phobias; Selected
- **Disruptive Behavior Disorders:** Oppositional Defiant Disorder (ODD) and Conduct Disorder (CD)
- **Mood Disorders:** Conditions involving depression and dysphoria, particularly in adolescence
- **Tic Disorders/Tou**
- **Specific Learning Disorders** (for example, reading or written expression)
- **Sleep Disorders:** Insomnia and disturbances in circadian rhythms are very prevalent.
- Motor Coordination Difficulties (Developmental Coord)



Fig 1: The Overlapping Comorbidity Landscape in ASD and ADHD

3. Etiology and Neurobiology: Shared Roots and Distinct Pathways

The high rate of accompaniment is highly evocative of the engrossment of imbrication etiological trails. The present theories suggest that it is multifactorial, where overlapping genetic risks, along with individual environmental risk, form a neurodevelopmental landscape, ultimately leading to the presentation of ASD, ADHD, or the typical co-occurrence of both [16].

3.1. Genetic and Molecular Underpinnings

Family and twins study has proved the most informative regarding common genetic influences. There are findings regarding the genetic correlation (rg) concerning ASD and ADHD traits between 0.50 and 0.70. This means that the majority of the genetic component in both disorders influences the other [17].

- **Twin Studies:** Twin studies conducted within the population have shown the concordance rate among monozygotic twins to be higher than among dizygotic twins, pointing towards the strong influence of the genetic component. The genetic factors for autistic and ADHD have a high correlation [18].
- **Family Studies:** First-degree relatives of individuals with ASD are susceptible not only to ASD, but also to ADHD. The overlapping gene effect in families proposes shared familial or genetic factors [18].

Molecular Genetics

- **Common Genetic Variants:** Genome-wide association studies, in addition to polygenic risk scoring, have shown that the same genetic variants that cause ASD increase the risk for ADHD, and vice versa. There exists a polygenic risk score for ADS, which can estimate the severity of ADS in the general population [19].
- **Rare Variants**: Copy number variants (CNVs), rare single nucleotide variants (SNVs), involving the deletion or duplication of the regions 16p11.2 and 22q11.2, as well as mutations of the CHD8, DYRK1A, and SHANK genes, involved in synaptic function or neurodevelopment, are known to be co-present in ASD, ADHD, or both [20].
- **Candidate Genes:** There are some genes that relate to the dopaminergic, norepinephrinergic, and serotonergic pathways that have been found to play a part in both. These include the following: DRD4 (dopamine receptor D4), SLC6A3 (also known as DAT1, the gene for the dopamine transporter), SNAP25 (also known as SNAP-25, synaptosomal-associated protein 25) [21].

3.2 Neuroanatomy and Neural Systems

Neuroimaging, predominantly conducted among the 'pure' diagnostic groups but increasingly in the comorbid phenotype, has found both common as well as distinctive patterns.

- **Frontal-Striatal Circuits:** This circuit consisting of the prefrontal cortex (dorsolateral and ventrolateral sectors), the anterior cingulate cortex, and the basal ganglion (striatum) is important in executive processing for the purposes of inhibition, working memory, or control of actions based on instructions or expectation versus execution of actions independent of prefrontal control but according to stimulus conditions. Dysfunctional circuitry in these networks has long been recognized in the pathophysiology of ADHD. Equivalent but sometimes subtle dysfunction in the frontal-striatal circuitry has also been detected in ASD patients, especially in the components of cognitive flexibility and response inhibition. The dysfunction of these particular networks in the combined subgroup of patients typically manifests most severely[22, 23].
- **Default Mode Network (DMN) and Salience Network:** The DMN, which is responsible for self-generated thought, social behaviors, and mind-wandering, is found to be dysfunctional in terms of functional connectivity, with both under-connectivity in ASD and hypo-activation in ADHD relative to tasks. The Salience Network, with function depending on the identification of behaviorally salient stimuli, is dysfunctional in terms of connectivity in both ASD and ADHD [24, 25].
- Social Brain Regions: Regions such as the amygdala (processing of emotion), superior temporal sulcus (perception of biological motion), temporoparietal junction (theory of mind), or medial prefrontal cortex (social cognition) are often affected in ASD. In the case

of the comorbid diagnosis, dysfunction in the "social brain" areas might combine with the inability for top-down control exerted by the fronto-striatal circuitry in generating the impulses that cause socially impulsive yet asually oblivious response [26, 27].

- Cerebellum and Corpus Callosum: The cerebellum, which is responsible for motor, coordination, and timing functions, has volume variations in both. The corpus callosum, which is the biggest white matter structure in the brain that connects the hemispheres, has also been found to be smaller in both ASD and ADHD, which may lead to issues related to hemispheric communication [28, 29].



Fig 2: Convergent and Divergent Neural Circuitry in ASD, ADHD, and their Comorbidity

3.3 Neurochemistry

Pharmacologic response offers inconclusive but strong evidence of the neurochemical hypothesis.

- **Dopamine/Norepinephrine:** The central efficacy of stimulants (e.g., methylphenidate/amphetamines) known to profoundly enhance synaptic levels of dopamine and norepinephrine in treating the symptoms of ADHD, even when co-morbid with ASD, strongly suggests the involvement of the dopamine and norepinephrine systems in the attentional and inhibitory problems common to both disorders. Functional anomalies within the dopamine and norepinephrine systems are probably the cause of the executive function and reward system anomalies observed in the co-morbid phenotype [30, 31].
- **Serotonin:** Involved in mood, anxiety, and repetitive behavior. Serotonin dysfunction has been widely noted in ASD cases. Children diagnosed with both ASD and ADHD often experience high levels of anxiety and obsessiveness, some of which could be serotonergic in nature. The partial responsiveness of this population in SSRI-mediated anxiety/irritability supports this theory [32, 33].
- **Glutamate/GABA:** The major inhibitory/excitatory neuronal transmitters of the brain. Impaired glutamate/GABA ratio is proposed as a leading cause of ASD underlying cortical hyperexcitability. There is potential inter-relationship of impaired glutamate/GABA ratio with catecholamine regulation proposed to account for the distinct sensory features of the comorbid patient [34, 35].

3.4 Environmental and Prenatal Factors

Commonly shared environmental risk factors could also play a role.

- **Prenatal Exposures**: Prenatal immune stimulation, preterm birth, low birth weights, and exposure to toxins such as lead, or alcohol have all been linked to an increased risk of both autism and ADHD.
- **Perinatal Complications:** Perinatal hypoxic-ischemic events can be considered general risk factors for numerous outcomes related to child development, including both disorders [35, 36].

The view that is emerging regarding the etiology is best characterized as the problem of "shared vulnerability with differential elaboration." A pattern of genetic and environmental risks acts on core neurodevelopmental mechanisms, especially those involved in the formation of synapses, the connection of neurons, and the development of neurotransmitter systems. Variations based on genetic elements, chance events, and a pattern of later life exposures can best be described as a vulnerability that begins to be realized most clearly as an impairment in social-communication, RRBs (autism spectrum disorder), inattention and impulsivity (ADHD), or a combination pattern, often with increased severity in common areas such as executive function [37, 38].

3.4 Clinical Presentation and Phenotypic Characterization

The child with comorbid ASD and ADHD cannot simply be seen as the child with ASD and then the child with ADHD. This is because, instead of the two conditions occurring separately, they occur synergistically, and this gives a different clinical profile, where the whole is often greater than the sum of the parts [39].

4. Social Communication and Interaction

Core Issue: The social motivation/understanding deficits of ASD collide with the impulsivity and poor self-regulation of ADHD.

Manifestations

- **Social Impulsivity:** Intrusive behaviors like interrupting conversations, grabbing toys, or invading others' personal space without the social understanding to realize these actions are inappropriate. This is different from the socially motivated but awkward attempts of a child with ASD alone, or the impulsive yet often socially aware child with ADHD alone [40, 41].
- **Monopolizing Conversations:** The circumscribed interests typical of ASD merge with ADHD impulsivity and verbosity in lengthy, one-sided monologues about a specific topic with a failure to read the listener's cues of boredom or disinterest [42].
- **Peer Relationships:** This is one of the most common and most detrimental combinations in human development. It lends itself to profound peer rejection. The child is often perceived as "annoying," "weird, "and "out of control." They are at extremely high risk for bullying and social isolation. Social awkwardness is magnified by their hyperactivity and poor turn-taking, making structured social learning very difficult [43].

4.1 Restricted, Repetitive Behaviors, Interests, and Activities (RRBs)

Core Issue: Needs for sameness and passionate pursuits (ASD) overlap with hyperactivity, impulsivity, and seeking rewards (ADHD) [44].

Manifestations

- **Hyperfixation with Ever-Changing Interests:** When children with autism choose an interest, like train schedules, it could be hyperfixating and autism-like. Yet their novelty-seeking, which comes from the ADHD, could lead to an abrupt change in interests from one thing to another and then back again with equal hyperfixation. What might look like an oppositional or flighty kid might be dealing with two vastly different modes of cognition [45].
- **Motor Restlessness as Stereotypy:** Sometimes, restlessness and motor agitation associated with ADHD and motor stereotypy in the ASD can be difficult to distinguish. When the two conditions are comorbid in a given child, the restlessness and motor agitation associated with hyperactivity can become more repetitive or stereotyped [46].
- **Stiffness and Catastrophic Responding:** The rigidity of following routines (ASD) and inability to regulate emotions and tolerate frustration (ADHD) causes extremely explosive and prolonged melt-downs when routines are disrupted. These episodes are far more extreme than the tantrums a young child or child with AD/HD adjusts to when frustrated [47].

4.3 Executive Function (EF): The Core Deficit

EF impairment is then regarded as the defining characteristic of the comorbid presentation and is described as being primarily responsible for functional disability**.**

- **Inhibition:** Extremely deficient. Examples include the following*:* Inhibiting behavior, meaning calling out, acting without thinking. Inhibiting thoughts, meaning the inability to stop and reverse intruding thoughts*/* [48].
- **Working Memory:** Highly impaired. This includes poor ability to retain information in mind for completing a task, following a series of instructions, and tracking possessions. This significantly affects academic and daily living activities*/* [49].
- **Executive Functioning/Cognitive Flexibility/Set-Shifting:** Unusually rigid. Has difficulty shifting from one task, thought, or method of problem-solving to another. The combination of this natural stubbornness about change, along with poor task-switching inherent in ADHD, makes it seemingly impossible for this individual to adapt when change happens [50].
- **Planning, Organizing and Initiating:** Severely impaired. Problems with dissecting tasks, an inability to prioritize time, difficulties with organizing supplies such as notebooks and a backpack, and an overall failure to initiate projects that are non-preferred. This results in an overwhelming sense of underachievement against intellectual ability [51].

Table 2: Differential Analysis of Executive Function Deficits

EF Domain	Typical Presentation in ASD	Typical Presentation in ADHD	Amplified Presentation in ASD+ADHD
Inhibition	May inhibit in familiar contexts but struggle with novel social rules. Difficulty inhibiting repetitive behaviors.	Global behavioral and cognitive inhibition failure across settings.	Profound global failure. Socially inappropriate impulsivity combined with inability to inhibit RRBs or compulsive actions.
Flexibility	Extreme difficulty with changes in routine, thinking style ("black-and-white").	Difficulty shifting attention between tasks; perseveration on a chosen activity.	Catastrophic inflexibility. Inability to handle any deviation from plan; meltdowns triggered by minor changes; rigid adherence to non-functional routines.
Working Memory	May be relatively spared for verbal info but impaired for complex social information.	Pervasive impairment across modalities.	Severe pervasive impairment. Forgets instructions, loses track of conversations and tasks constantly.
Planning/Organization	May create complex, rigid systems for organizing interests but fail at general organization.	Chronic disorganization, poor time management, procrastination.	Functional disorganization. Inability to organize any aspect of daily life (homework, self-care, room). Cannot plan even simple sequences.

4.4 Emotional and Behavioral Dysregulation

Irritability, Outbursts of Anger: Pervasively present, extremely intense. Low tolerance to frustration (ADHD). Meets the criterions for the inflexibility present in ASD. Outbursts of anger/meltdowns are hard to console*/* [52].

Anxiety: High levels of both general and social kinds of anxiety exist. The child is always trying to make sense of an unpredictable world (ASD) while being physically out of control inside (ADHD) while facing the pressures of school failure-related performance anxieties [53].

Sensory Processing in Autism

Sensory sensitivities (to sounds, touch, lights), or sensory-seeking behaviors, are at the heart of ASD. The combined child could have sensory overload that leads to hyperactivity, impulsiveness, or meltdowns in the child. Hyperactivity could result in sensory-seeking behavior (touching everything in a room, breaking objects with hands) [54].

4.5 Adaptive Functioning and Daily Living Skills

The gap between intellectual ability and real-world functioning is typically largest in the comorbid group. Skills in communication, daily living (e.g., hygiene, chores), and socialization are markedly impaired due to the combination of social deficits, executive dysfunction, and often co-occurring motor clumsiness. This has profound implications for independence in adolescence and adulthood [55].



Fig 3: The Interactive Phenotype Model of ASD and ADHD

5. Diagnostic Assessment: Navigating Complexity and Overlap

Arriving at an accurate and comprehensive diagnosis involves the most important work in planning an effective intervention. The diagnostic stage requires an extremely thorough process. Arriving at an accurate, comprehensive diagnosis represents the single most important action within planning an effective intervention. Arriving at an accurate, comprehensive diagnosis involves the most important work in planning an effective intervention [56].

5.1. Core Diagnostic Challenges

- **Symptom Masking and Attribution:** Hyperactivity in the context of ADHD might camouflage the symptom of social withdrawal in the case of AS, or the intensely AS-related interest might convincingly demonstrate the presence of hyperfocus. On the other hand, social also [57].
- **The "Primary" Diagnosis Fallacy:** It is common in clinical practice that the presenting condition will receive a diagnosis first. For example, hyperactivity, leading to an ADHD diagnosis, may mask social difficulties in an ASD diagnosis. This may delay an ASD diagnosis by as much as a few years [58].
- **Measurement Limitations:** Diagnostic algorithms underlying common measures of ASD (e.g., ADOS-2) were established on populations in which the presence of ADHD was a contraindication. They may not adequately reflect the profile of the child who actually scores high. Right for eye contact or attempts to initiate social interactions due to impulsivity but with seriously poor reciprocity [59].
- **Differentiating from Other Conditions:** ODD, anxiety disorders, and learning disabilities can mimic or co-occur with both ASD and ADHD, adding layers of complexity [60].

5.2 Essential Components of a Comprehensive Assessment

A thorough valuation is a hypothesis-testing procedure, not a checklist exercise [61-65].

Table 3: Comprehensive Diagnostic Assessment Protocol for Suspected ASD and ADHD

Assessment Component	Purpose & Key Tools	Special Considerations for Comorbidity
1. Developmental & Clinical History	Purpose: Establish early trajectory, symptom evolution, functional impact. Tools: Semi-structured interview (e.g., K-SADS, 3Di), detailed history from parents.	Probe for early social communication markers (joint attention, pretend play) alongside early regulatory problems (colic, sleep, extreme activity). Ask about the *quality* of social engagement, not just presence.
2. Direct Observation & ASD-Specific Measures	Purpose: Objectively assess social-communication skills and RRBs. Gold Standard: Autism Diagnostic Observation Schedule, 2nd Ed. (ADOS-2).	Inform the ADOS-2 administrator of suspected ADHD. Observe if social initiations are reciprocal or impulsive/tangential. Note if RRBs are stereotyped or more generalized fidgeting.
3. ADHD-Specific	Purpose: Quantify inattention, hyperactivity, impulsivity	CPTs can be useful but interpret with caution; inattention

Measures	across settings. Tools: Parent/Teacher rating scales (Conners 3, Vanderbilt, ADHD-RS-5); continuous performance tests (CPTs, e.g., TOVA, Conners CPT).	may be due to social disinterest (ASD) or core attentional deficit (ADHD). Rating scales from both school and home are mandatory.
4. Cognitive & Academic Testing	Purpose: Establish intellectual profile, identify learning disabilities, inform intervention. Tools: IQ test (WISC-V, Stanford-Binet), academic achievement tests (WIAT-III, Woodcock-Johnson).	Look for scatter in IQ profiles (often high Matrix Reasoning, low Coding or Working Memory). Assess executive functions directly (e.g., NEPSY-II, DKEFS).
5. Speech-Language & Occupational Therapy	Purpose: Assess pragmatic language, sensory-motor integration, adaptive living skills. Tools: Formal assessments by SLP and OT.	Crucial for functional planning. Pragmatic assessment must account for impulsivity in conversation. OT eval should differentiate sensory seeking from general hyperactivity.
6. Assessment of Comorbidities	Purpose: Rule out or identify other conditions. Tools: Anxiety/depression scales (RCADS, MASC-2), screen for tics, sleep history.	High likelihood of anxiety, ODD. Assess sleep hygiene and problems thoroughly.

5.3 The Diagnostic Formulation

The final formulation should respond to the following questions: Does this child have a DSM-5 diagnosis of ASD Of ADHD Each piece of evidence should be evaluated in terms of the DSM-5 criteria on its own, but how they impact on each other is described in narrative form. A helpful way to do this is to make a profile in which you list.

Confirmed Diagnoses: ASD, ADHD Combined Presentation, etc.

- **Rule-Outs/Rule-Ins:** for example, “Generalized Anxiety Disorder, confirmed”; “Specific Learning Disorder with impairment in written expression [66].
- **Functional Analysis of Symptoms:** "A description of how the symptoms of ASD and symptoms of ADHD interact to create the core problems in the child. For example, "Social impulsivity seen in ADHD impairs the child's practice of social skills, which are inherently lacking because of ASD." This is sometimes abbreviated as "Symptom Summary" or "Symptom Interactions" [67].
- **Strengths and Interests:** Strengths and interests identification remain important in self-esteem and motivation building [68].



Fig 4: The Diagnostic Decision Tree for Differentiating and Co-Diagnosing ASD and ADHD

6. Management and Intervention: An Integrated, Multimodal Framework

Operational management for ASD and ADHD requires an integrated, custom-made, and often intensive methodology. Interventions must target the interactive symptoms, not just treat each disorder in equivalent. The keystone is a cooperative team involving parents, clinicians, educators, and often speech/occupational therapists [69].

6.1 Foundational Strategies: Psychoeducation and Environmental Modifications

Before any precise therapy, founding considerate and a compassionate setting is overriding.

- **Psychoeducation:** Instruct parents, teachers, and the child (in developmentally apposite conducts) about *both* surroundings and how they interrelate. This lessens blame, fosters sympathy, and aligns opportunities [70].

Environmental Modifications

- **Structure and Predictability:** Use pictorial timetables, unblemished procedures, and improvement cautions for changeovers. This condenses nervousness and breakdowns stanching from intransigence [71].
- **Executive Function Scaffolds:** Provide peripheral organizers (checklists, planners, timers), break tasks into micro-steps, use graphic organizers for journalism, and have a nominated, clutter-free workspace.
- **Sensory and Behavioral Accommodations:** Offer sensory breaks, alternative seating, noise-canceling headphones, and fidget tools. Use clear, concise, and positive instructions. Implement a consistent, predictable reward system for target behaviors [71].

- **Social-Communication Supports:** Use social stories™ and comic strip conversations to explicitly teach social rules and scripts. Create protected, structured social opportunities with supportive peers (e.g., facilitated playdates, social skills groups) [72].

6.2 Psychosocial and Behavioral Interventions

- **Parent Training/Behavioral Parent Training (BPT):** Evidence-based curriculums like Parent-Child Communication Therapy (PCIT), changed for growth-related illnesses, or customary BPT programs are first-line interferences. They communicate parents hands-on approaches to survive comportment, improve compliance, diminish oppositionality, and sponsor positive exchanges. For the comorbid child, reworkings focus on organization emotional dysregulation and instruction skills in a highly well-thought-out way [73, 74].

- **School-Based Interventions**

a) **Individualized Education Program (IEP) or 504 Plan:** Indispensable for acquiring adjustments and assistances [74].

b) **Functional Behavioral Assessment (FBA) and Behavior Intervention Plan (BIP):** An FBA ascertains the qualifications (A), performances (B), and significances (C) of problematical activities. The BIP then frameworks proactive approaches, replacement comportments, and response processes. This is crucial for concentrating disintegrations, work refusal, and social encounters [75].

c) **Executive Function Coaching:** Uninterrupted teaching of organization, planning, and study skills within the school context [75].

Social Skills Training (SST): Must be explicitly adapted. Effective SST for this group needs to:

1. Target core deficits (e.g., perspective-taking, emotion recognition).
2. Incorporate strategies for cultivating helpfulness and impulse control *within* social circumstances (e.g., "stop and think" before speaking, listening with full attention).
3. Use highly structured, anticipated formats with clear rules.
4. Include oversimplification strategies, such as in-vivo education during recess or lunch [76].

Cognitive Behavioral Therapy (CBT): For school-age children and adolescents, CBT adapted for ASD (more concrete, visual, structured, with a focus on emotion sympathy) is operational for treating co-occurring anxiety, depression, and anger administration [77].

6.3 Pharmacological Management: Medication is often indispensable component to diminish core ADHD symptoms, which in turn can permit the child to assistance more abundantly from behavioral and educational intercessions [78].

- **Stimulants (Methylphenidate and Amphetamine-based):**

a) **Efficacy:** Multiple randomized controlled trials (RCTs) and meta-analyses authorize stimulants are applicable in reducing ADHD symptoms (inattention, hyperactivity, impulsivity) in children with ASD. Effect sizes are generally large, though somewhat smaller than in ADHD alone [79].

b) **Tolerability:** Side effects are more common and can be more severe. These include reduced appetite, insomnia, irritability, emotional lability, and increased stereotypic behaviors or tics. A subset of children with ASD may experience marked behavioral worsening ("behavioral rebound" or paradoxical agitation) [80].

c) **Practice:** A **"start low, go slow"** titration is mandatory. Begin with a very low dose (e.g., methylphenidate 5mg daily) and increase gradually while closely monitoring intention symptoms and side effects. Long-acting formulations are often preferred for smoother coverage [81].

Non-Stimulants

- **Atomoxetine:** A selective norepinephrine reuptake inhibitor. RCTs show efficacy for ADHD symptoms in ASD. It may have a positive influence on emotional lability and anxiety. Recompenses include no abuse impending and once-daily dosing. Shortcomings include a slower onset of action (4-8 weeks) and potential monogram side effects like nausea, sedation, and irritability [82].
- **Alpha-2 Adrenergic Agonists (Guanfacine XR, Clonidine):** These are particularly useful for treating hyperactivity, impulsivity, and emotional volatility. They are often effective for sleep onset problems. Guanfacine XR is generally better tolerated due to its longer half-life and more selective action. These are frequently used as monotherapy or as an adjunct to stimulants to allow for lower stimulant dosing and better control of emotional side effects [83].

Medications for Co-occurring Conditions

- **Atypical Antipsychotics (Risperidone, Aripiprazole):** FDA-approved for irritability and aggression in ASD. They are **not** first-line for core ADHD symptoms but may be added if severe aggression, self-injury, or tantrums persist despite other treatments. Significant metabolic and neurological side effects require careful monitoring [84].
- **Selective Serotonin Reuptake Inhibitors (SSRIs):** Used for comorbid anxiety disorders, obsessive-compulsive symptoms, or depression. Use with caution, starting at very low doses, as some individuals with ASD are prone to behavioral activation (increased energy, irritability, insomnia) [85].

Table 4: Detailed Pharmacotherapy Algorithm for ADHD Symptoms in ASD and ADHD

Step	Intervention	Rationale & Monitoring
Step 1: Foundation & Trial	Begin low-dose stimulant (e.g., Methylphenidate LA 10mg). Titrate slowly every 5-7 days.	First-line for core ADHD symptoms. Monitor target symptoms (teacher/parent ratings), appetite, sleep, mood, and emergence of tics or stereotypies.
Step 2A: Partial Response	If partial response but tolerable, optimize stimulant dose to maximum tolerated/effective dose.	Seek optimal efficacy while managing side effects. Consider switching to an alternative stimulant (methylphenidate to amphetamine or vice versa) if poor response.
Step 2B: Intolerable Side Effects	If side effects (irritability, mood lability) limit stimulant use, add an alpha-2 agonist (Guanfacine XR).	Guanfacine can mitigate emotional side effects of stimulants and treat residual hyperactivity. Allows for use of lower stimulant dose.
Step 3: Alternative Monotherapy	If stimulants are ineffective or poorly tolerated, switch to Atomoxetine. Titrate to target dose (e.g., 1.2 mg/kg/day).	Non-stimulant option. Monitor for GI side effects, sedation, and mood changes. Full effect may take 8-12 weeks.
Step 4: Combination Therapy	Consider combinations: Stimulant + Guanfacine, or Stimulant + Atomoxetine (with caution).	For complex, treatment-resistant cases. Requires expert management and careful monitoring for additive side effects.
Step 5: Adjunct for Irritability	If severe aggression/irritability persists, consider adding low-dose Risperidone or Aripiprazole.	**Targets irritability, not core ADHD.** Regular monitoring of weight, BMI, glucose, lipids, and extrapyramidal symptoms required.



Fig 5: Integrated Stepped-Care Model for ASD and ADHD Management

7. Prognosis, Outcomes, and Lifespan Considerations

Children with co-occurring ASD and ADHD face a more challenging developmental trajectory compared to those with either condition alone. The interactive impairments lead to cumulative deficits across multiple domains of life [86].

7.1 Academic Outcomes

They are at the highest risk for significant academic underachievement. Executive dysfunction leads to profound difficulties with organization, task completion, and studying. Social problems contribute to school avoidance and poor relationships with teachers and peers. Rates of grade retention, need for special education services, and school disciplinary actions are elevated. The likelihood of completing secondary education and pursuing post-secondary education is lower [86].

7.2 Social and Peer Outcomes

Peer rejection and social isolation are all but a universal experience in the child years. The consequences are pervasive: extreme loneliness, low self-esteem, and an increased risk for bullying and victimization. The risk for deviant peer affiliation increases in adolescence, which in turn may contribute to conduct problems. Creating and maintaining romantic relationships is significantly more challenging [87].

7.3 Psychiatric Comorbidity and Mental Health: There is an increased risk of co-existing mental health problems. An anxiety or depression issue becomes more prominent among the young. These feelings of persistent failure, social rejection, and response dysregulation contribute to their high rates. Suicidal ideas and self-harm tendencies become serious concerns among young people [88].

7.4 Adaptive Functioning and Independence: The area of greatest concern is, perhaps, adaptive functioning, or living skills necessary for independent living. Weaknesses in executive functioning, socialization, and sometimes activities of daily living (cooking, cleaning, financial management) open an enormous chasm between intellectual abilities and independent living. These young adults with ASD and ADHD are often severely dependent on their families, with very limited independent living, competitive employment, and successful romantic relationship outcomes [89].

7.5 Positive Outcomes and Resilience Factors: Despite these challenges, positive outcomes are possible and must

be fostered. Protective factors include: Early, accurate diagnosis and intervention.

- Average or higher intellectual ability.
- Strong family support and advocacy.
- The presence of a special talent, interest, or skill that can be channeled into vocational or recreational pursuits.
- Development of self-awareness and self-advocacy skills.
- Finding a supportive peer group or community (e.g., through shared interests) [89-92].

Table 5: Comparative Long-Term Adult Outcomes

Outcome Domain	ASD Alone (HF)	ADHD Alone	ASD and ADHD Comorbid	Implications
Educational Attainment	Variable; may complete university in areas of strength.	Lower rates of college completion; academic underachievement.	Lowest rates of post-secondary education. High school completion often a struggle.	Need for continued academic support and career counseling into adulthood.
Employment	May find niche employment related to interests; underemployment common.	Job instability; problems with punctuality, organization.	Highest under/unemployment. Difficulties with social demands of workplace and executive function tasks.	Supported employment programs, job coaching essential.
Independent Living	Many live semi-independently or with support.	Most live independently, though may struggle with organization.	Majority require significant support (live with family, supported housing).	Focus on adaptive skills training from adolescence.
Social Relationships	Small social network; may have a partner.	Social networks exist but may be conflictual; higher divorce rates.	Extreme social isolation. Very low rates of long-term romantic partnerships.	Lifelong support for social connection needed.
Mental Health	High rates of anxiety, depression.	High rates of substance use, personality disorders, depression.	Greatest psychiatric burden: Anxiety, depression, low self-esteem, suicidal ideation.	Lifelong access to mental health services critical.
Quality of Life	Often reduced.	Often reduced.	Most significantly reduced across multiple domains.	Interventions must target functional outcomes and well-being, not just symptom reduction.



Fig 6: Developmental Trajectories from Childhood to Adulthood

8. Controversies, Gaps, and Future Directions

Despite significant advances, numerous controversies and research gaps remain.

8.1 Nosological and Conceptual Debates

Is it a Distinct Subtype: Some scholars view ASD and ADHD as being a new subtype with its own etiology and course, instead of a comorbidity of two known entities.

Dimensional vs. Categorical: There is an RDoC approach to encourage cross-dimensional rather than purely categorical research to study dimensional constructs such as social communication or cognitive control. DOIng so might provide more insight into the comorbid phenotype [93].

The Role of ID: Primarily, the area has been concerned with «high-functioning» children. The syndrome and the problems of children with ASD and ADHD as well as the

syndrome combined with intellectually disabled people are radically under researched [94].

8.2 Assessment and Diagnosis

Need for New Tools: There is an urgent need for diagnostic instruments and algorithms specifically validated for the comorbid population. The ADOS-2 algorithms may need refinement for this group [95].

Female Presentation: The unique presentation of girls with ASD and ADHD, who may better mask social deficits but suffer intense internalizing symptoms, requires dedicated study to improve early identification [96].

8.3 Treatment and Intervention

- **Treatment Sequencing:** What is the optimal order? Does stabilizing ADHD symptoms with medication *first* enhance the efficacy of subsequent behavioral therapies for social skills or anxiety? Large, pragmatic trials are needed [97].
- **Integrated Treatment Protocols:** Manualized treatments specifically designed for ASD and ADHD, combining elements of EF training, social skills, and emotion regulation in one cohesive package, are in their infancy and need development and testing [97].
- **Pharmacogenetics:** Can we predict who will respond to stimulants vs. atomoxetine, or who is at high risk for side effects, based on genetic markers? This promise of personalized medicine remains largely unrealized [97].
- **Adult Services:** The service cliff faced by these individuals upon leaving secondary school is severe. Research on effective interventions and support models for adults with ASD and ADHD is desperately lacking [97].

8.4 Neurobiological Research

Longitudinal neuroimaging studies tracking brain development in the comorbid phenotype from childhood through adolescence are needed to understand neural trajectories and identify potential biomarkers for prognosis or treatment response [98].

9. Conclusion

Comorbidity between autism spectrum disorder and Attention-Deficit/Hyperactivity Disorder in childhood is a common, valid, and highly impactful clinical phenomenon. Removing the diagnostic barrier in DSM-5 was a necessary correction, bringing classification in line with both clinical observation and empirical research. We can now consider this comorbidity not as an unusual coincidence but rather as a very probable result of common genetic vulnerabilities influencing overlapping neural systems.

The resultant phenotype is one of amplified impairment, with social-communication deficits turbocharged by impulsivity, the need for sameness crashing against poor emotional regulation, and a "double hit" to executive functions crippling adaptive functioning. This leads to a child at high risk for academic failure, peer rejection, family stress, and a cascade of secondary mental health problems.

This challenge requires the clinician to have sophisticated assessment skills to tease out overlapping symptoms and commit to an integrated management strategy that is multimodal and persistent. There is no single intervention. Here, success is made possible through the integration of high-quality methods involving psychoeducation, environmental engineering, parent behavioral training, support in the school setting, appropriate psychosocial interventions, and careful pharmacotherapy, which in some instances may be the Looking ahead, there is a pressing need for attention to be focused on the development of assessment measures for the co-occurrence, the development of models for treatment across the co-occurrence, and the extension of research into adolescence and adulthood as well. The hope is to be able to not only recognize the co-occurrence, but to understand its very nature, with the aim of providing a dramatically improved developmental trajectory for these children at the intersection for whom there is such a high level of need, but also such great hope for positive impact.

References

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition, Revised. Washington, DC: American Psychiatric Association; 1987.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC: American Psychiatric Association; 1994.
3. Antshel KM, Russo N. Autism Spectrum Disorders and ADHD: Overlapping Phenomenology, Diagnostic Issues, and Treatment Considerations. Curr Psychiatry Rep. 2019;21(5):34. DOI:10.1007/s11920-019-1020-5
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. Arlington, VA: American Psychiatric Association; 2013.
5. Leitner Y. The co-occurrence of autism and attention deficit hyperactivity disorder in children - what do we know? Front Hum Neurosci. 2014;8:268. DOI:10.3389/fnhum.2014.00268
6. Gillberg C. The ESSENCE in child psychiatry: Early Symptomatic Syndromes Eliciting Neurodevelopmental Clinical Examinations. Res Dev Disabil. 2010;31(6):1543-51. DOI:10.1016/j.ridd.2010.06.002
7. Lai MC, Kassee C, Besney R, *et al*. Prevalence of co-occurring mental health diagnoses in the autism population: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(10):819-29. DOI:10.1016/S2215-0366(19)30289-5
8. Rong Y, Yang CJ, Jin Y, Wang Y. Prevalence of attention-deficit/hyperactivity disorder in individuals with autism spectrum disorder: a meta-analysis. Res Autism Spectr Disord. 2021;83:101759. DOI:10.1016/j.rasd.2021.101759
9. Joshi G, Faraone SV, Wozniak J, *et al*. Symptom Profile of ADHD in Youth With High-Functioning Autism Spectrum Disorder: A Comparative Study in Psychiatrically Referred Populations. J Atten Disord. 2017;21(10):846-55. DOI:10.1177/1087054714543368
10. Grzadzinski R, Dick C, Lord C, Bishop S. Parent-reported and clinician-observed autism spectrum disorder (ASD) symptoms in children with attention deficit/hyperactivity disorder (ADHD): implications for practice under DSM-5. Mol Autism. 2016;7:7. DOI:10.1186/s13229-016-0072-1
11. Stevens T, Peng L, Barnard-Brak L. The comorbidity of ADHD in children diagnosed with autism spectrum

disorder. Res Autism Spectr Disord. 2016;31:11-8. DOI:10.1016/j.rasd.2016.07.003
12. Antshel KM, Zhang-James Y, Wagner KE, *et al*. An update on the comorbidity of ADHD and ASD: a focus on clinical management. Expert Rev Neurother. 2016;16(3):279-93. DOI:10.1586/14737175.2016.1146591
13. Rommelse NN, Franke B, Geurts HM, *et al*. Shared heritability of attention-deficit/hyperactivity disorder and autism spectrum disorder. Eur Child Adolesc Psychiatry. 2010;19(3):281-95. DOI:10.1007/s00787-010-0092-x
14. Reiersen AM, Constantino JN, Todd RD. Co-occurrence of motor problems and autistic symptoms in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2008;47(6):662-72. DOI:10.1097/CHI.0b013e31816bff8b
15. Gjevik E, Eldevik S, Fjæran-Granum T, Sponheim E. Kiddie-SADS reveals high rates of DSM-IV disorders in children and adolescents with autism spectrum disorders. J Autism Dev Disord. 2011;41(6):761-9. DOI:10.1007/s10803-010-1095-7
16. Ronald A, Hoekstra RA. Autism spectrum disorders and autistic traits: a decade of new twin studies. Am J Med Genet B Neuropsychiatr Genet. 2011;156B(3):255-74. DOI:10.1002/ajmg.b.31159
17. Polderman TJ, Hoekstra RA, Posthuma D, Larsson H. The co-occurrence of autistic and ADHD dimensions in adults: an etiological study in 17, 770 twins. Transl Psychiatry. 2014;4(9):e435. DOI:10.1038/tp.2014.84
18. Ghirardi L, Brikell I, Kuja-Halkola R, *et al*. The familial co-aggregation of ASD and ADHD: a register-based cohort study. Mol Psychiatry. 2018;23(2):257-62. DOI:10.1038/mp.2017.17
19. Grove J, Ripke S, Als TD, *et al*. Identification of common genetic risk variants for autism spectrum disorder. Nat Genet. 2019;51(3):431-44. DOI:10.1038/s41588-019-0344-8
20. Satterstrom FK, Kosmicki JA, Wang J, *et al*. Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism. Cell. 2020;180(3):568-584.e23. DOI:10.1016/j.cell.2019.12.036
21. Gizer IR, Ficks C, Waldman ID. Candidate gene studies of ADHD: a meta-analytic review. Hum Genet. 2009;126(1):51-90. DOI:10.1007/s00439-009-0694-x
22. Di Martino A, Zuo XN, Kelly C, *et al*. Shared and distinct intrinsic functional network centrality in autism and attention-deficit/hyperactivity disorder. Biol Psychiatry. 2013;74(8):623-32. DOI:10.1016/j.biopsych.2013.02.011
23. Cortese S, Kelly C, Chabernaud C, *et al*. Toward systems neuroscience of ADHD: a meta-analysis of 55 fMRI studies. Am J Psychiatry. 2012;169(10):1038-55. DOI:10.1176/appi.ajp.2012.11101521
24. Uddin LQ, Supekar K, Lynch CJ, *et al*. Salience network-based classification and prediction of symptom severity in children with autism. JAMA Psychiatry. 2013;70(8):869-79. DOI:10.1001/jamapsychiatry.2013.104
25. Christakou A, Murphy CM, Chantiluke K, *et al*. Disorder-specific functional abnormalities during sustained attention in youth with attention deficit hyperactivity disorder (ADHD) and with Autism. Mol Psychiatry. 2013;18(2):236-44. DOI:10.1038/mp.2011.185
26. Chevallier C, Kohls G, Troiani V, *et al*. The social motivation theory of autism. Trends Cogn Sci. 2012;16(4):231-9. DOI:10.1016/j.tics.2012.02.007
27. Chantiluke K, Christakou A, Murphy CM, *et al*. Disorder-specific functional abnormalities during temporal discounting in youth with Attention Deficit Hyperactivity Disorder (ADHD), Autism and comorbid ADHD and Autism. Psychiatry Res Neuroimaging. 2014;223(2):113-20. DOI:10.1016/j.pscychresns.2014.04.006
28. Fatemi SH, Aldinger KA, Ashwood P, *et al*. Consensus paper: pathological role of the cerebellum in autism. Cerebellum. 2012;11(3):777-807. DOI:10.1007/s12311-012-0355-9
29. Valera EM, Faraone SV, Murray KE, Seidman LJ. Meta-analysis of structural imaging findings in attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007;61(12):1361-9. DOI:10.1016/j.biopsych.2006.06.011
30. Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother. 2014;48(2):209-25. DOI:10.1177/1060028013510699
31. Posey DJ, Aman MG, McCracken JT, *et al*. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiatry. 2007;61(4):538-44. DOI:10.1016/j.biopsych.2006.09.028
32. Muller CL, Anacker AMJ, Veenstra-VanderWeele J. The serotonin system in autism spectrum disorder: From biomarker to animal models. Neuroscience. 2016;321:24-41. DOI:10.1016/j.neuroscience.2015.11.010
33. Kolevzon A, Mathewson KA, Hollander E. Selective serotonin reuptake inhibitors in autism: a review of efficacy and tolerability. J Clin Psychiatry. 2006;67(3):407-14.
34. Cellot G, Cherubini E. GABAergic signaling as therapeutic target for autism spectrum disorders. Front Pediatr. 2014;2:70. DOI:10.3389/fped.2014.00070
35. Gardener H, Spiegelman D, Buka SL. Prenatal risk factors for autism: comprehensive meta-analysis. Br J Psychiatry. 2009;195(1):7-14. DOI:10.1192/bjp.bp.108.051672
36. Brynge M, Sjöqvist H, Gardner RM, *et al*. Maternal infection during pregnancy and likelihood of autism and intellectual disability in children in Sweden: a negative control and sibling comparison study. Lancet Psychiatry. 2022;9(10):782-91. DOI:10.1016/S2215-0366(22)00264-4
37. Rommelse NN, Geurts HM, Franke B, *et al*. A review on cognitive and brain endophenotypes that may be common in autism spectrum disorder and attention-deficit/hyperactivity disorder and facilitate the search for pleiotropic genes. Neurosci Biobehav Rev. 2011;35(6):1363-96. DOI:10.1016/j.neubiorev.2011.02.015
38. Sokolova E, Oerlemans AM, Rommelse NN, *et al*. A Causal and Mediation Analysis of the Comorbidity Between Attention Deficit Hyperactivity Disorder

(ADHD) and Autism Spectrum Disorder (ASD). J Autism Dev Disord. 2017;47(6):1595-604. DOI:10.1007/s10803-017-3083-7
39. Antshel KM, Zhang-James Y, Faraone SV. The comorbidity of ADHD and autism spectrum disorder. Expert Rev Neurother. 2013;13(10):1117-28. DOI:10.1586/14737175.2013.840417
40. Yerys BE, Wallace GL, Sokoloff JL, *et al*. Attention deficit/hyperactivity disorder symptoms moderate cognition and behavior in children with autism spectrum disorders. Autism Res. 2009;2(6):322-33. DOI:10.1002/aur.103
41. Rao PA, Landa RJ. Association between severity of behavioral phenotype and comorbid attention deficit hyperactivity disorder symptoms in children with autism spectrum disorders. Autism. 2014;18(3):272-80. DOI:10.1177/1362361312470494
42. Taurines R, Schwenck C, Westerwald E, *et al*. ADHD and autism: differential diagnosis or overlapping traits? A selective review. Atten Defic Hyperact Disord. 2012;4(3):115-39. DOI:10.1007/s12402-012-0086-2
43. Tye C, Asherson P, Ashwood KL, *et al*. Attention and inhibition in children with ASD, ADHD and co-morbid ASD+ADHD: an event-related potential study. Psychol Med. 2014;44(5):1101-16. DOI:10.1017/S0033291713001049
44. Hervás A, Rueda I, *et al*. Autism Spectrum Disorder and Attention Deficit Hyperactivity Disorder: An update on their comorbidity. Actas Esp Psiquiatr. 2014;42(1):36-48.
45. Van der Meer JM, Oerlemans AM, van Steijn DJ, *et al*. Are autism spectrum disorder and attention-deficit/hyperactivity disorder different manifestations of one overarching disorder? Cognitive and symptom evidence from a clinical and population-based sample. J Am Acad Child Adolesc Psychiatry. 2012;51(11):1160-72.e3. DOI:10.1016/j.jaac.2012.08.024
46. May T, Cornish K, Rinehart NJ. Does gender matter? A one year follow-up of autistic, attention and anxiety symptoms in high-functioning children with autism spectrum disorder. J Autism Dev Disord. 2014;44(5):1077-86. DOI:10.1007/s10803-013-1962-0
47. Green JL, Rinehart N, Anderson V, *et al*. Autism spectrum disorder symptoms in children with ADHD: a community-based study. Res Dev Disabil. 2015;47:175-84. DOI:10.1016/j.ridd.2015.09.016
48. Craig F, Lamanna AL, Margari F, *et al*. Overlap Between Autism Spectrum Disorders and Attention Deficit Hyperactivity Disorder: Searching for Distinctive/Common Clinical Features. Autism Res. 2015;8(3):328-37. DOI:10.1002/aur.1449
49. Ames CS, White SJ. Are ADHD traits dissociable from the autistic profile? Links between cognition and behaviour. J Autism Dev Disord. 2011;41(3):357-63. DOI:10.1007/s10803-010-1049-0
50. Sinzig J, Walter D, Doepfner M. Attention deficit/hyperactivity disorder in children and adolescents with autism spectrum disorder: symptom or syndrome? J Atten Disord. 2009;13(2):117-26. DOI:10.1177/1087054708326261
51. Demopoulos C, Hopkins J, Davis A. A comparison of social cognitive profiles in children with autism spectrum disorders and attention-deficit/hyperactivity disorder: a matter of quantitative but not qualitative difference? J Autism Dev Disord. 2013;43(5):1157-70. DOI:10.1007/s10803-012-1657-y
52. Simonoff E, Pickles A, Charman T, *et al*. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry. 2008;47(8):921-9. DOI:10.1097/CHI.0b013e318179964f
53. Guttmann-Steinmetz S, Gadow KD, Devincent CJ. Oppositional defiant and conduct disorder behaviors in boys with autism spectrum disorder with and without attention-deficit hyperactivity disorder versus several comparison samples. J Autism Dev Disord. 2009;39(7):976-85. DOI:10.1007/s10803-009-0706-7
54. Lane AE, Young RL, Baker AE, Angley MT. Sensory processing subtypes in autism: association with adaptive behavior. J Autism Dev Disord. 2010;40(1):112-22. DOI:10.1007/s10803-009-0840-2
55. Totsika V, Hastings RP, Emerson E, *et al*. A population-based investigation of behavioural and emotional problems and maternal mental health: associations with autism spectrum disorder and intellectual disability. J Child Psychol Psychiatry. 2011;52(1):91-9. DOI:10.1111/j.1469-7610.2010.02295.x
56. Ozonoff S, Goodlin-Jones BL, Solomon M. Evidence-based assessment of autism spectrum disorders in children and adolescents. J Clin Child Adolesc Psychol. 2005;34(3):523-40. DOI:10.1207/s15374424jccp3403_8
57. Matson JL, Rieske RD, Williams LW. The relationship between autism spectrum disorders and attention-deficit/hyperactivity disorder: an overview. Res Dev Disabil. 2013;34(9):2475-84. DOI:10.1016/j.ridd.2013.05.021
58. Zwick GP. ADHD and Autism Spectrum Disorder: Differential Diagnosis or Combined Conditions. J Psychol Clin Psychiatry. 2017;8(5):00509. DOI:10.15406/jpcpy.2017.08.00509
59. Grzadzinski R, Huerta M, Lord C. DSM-5 and autism spectrum disorders (ASDs): an opportunity for identifying ASD subtypes. Mol Autism. 2013;4(1):12. DOI:10.1186/2040-2392-4-12
60. Kentrou V, de Veld DM, Mataw KJ, Begeer S. Delayed autism spectrum disorder recognition in children and adolescents previously diagnosed with attention-deficit/hyperactivity disorder. Autism. 2019;23(4):1065-72. DOI:10.1177/1362361318785171
61. Kaufman J, Birmaher B, Brent D, *et al*. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36(7):980-8. DOI:10.1097/00004583-199707000-00021
62. Lord C, Rutter M, DiLavore PC, *et al*. Autism Diagnostic Observation Schedule-2nd edition (ADOS-2). Los Angeles, CA: Western Psychological Corporation; 2012.
63. Conners CK. Conners 3rd edition. Toronto, ON: Multi-Health Systems; 2008.
64. Wolraich ML, Lambert W, Doffing MA, *et al*. Psychometric properties of the Vanderbilt ADHD diagnostic parent rating scale in a referred population. J

Pediatr Psychol. 2003;28(8):559-67. DOI:10.1093/jpepsy/jsg046
65. Wechsler D. Wechsler Intelligence Scale for Children-Fifth Edition. San Antonio, TX: Pearson; 2014.
66. Sprenger L, Bühler E, Poustka L, *et al*. Impact of ADHD symptoms on autism spectrum disorder symptom severity. Res Dev Disabil. 2013;34(10):3545-52. DOI:10.1016/j.ridd.2013.07.028
67. Jang J, Matson JL, Williams LW, Tureck K. Autism spectrum disorders and ADHD: overlapping phenomenology, diagnostic issues, and treatment considerations. Curr Psychiatry Rep. 2013;15(2):335. DOI:10.1007/s11920-012-0335-2
68. Myles BS, Simpson RL. Asperger syndrome: a guide for educators and parents. 2nd ed. Austin, TX: Pro-Ed; 2002.
69. National Institute for Health and Care Excellence (NICE). Autism spectrum disorder in under 19s: support and management. NICE guideline [CG170]. 2013.
70. Barkley RA. Attention-deficit hyperactivity disorder: A handbook for diagnosis and treatment. 4th ed. New York, NY: Guilford Press; 2015.
71. Dawson P, Guare R. Executive skills in children and adolescents: A practical guide to assessment and intervention. 3rd ed. New York, NY: Guilford Press; 2018.
72. Gray C. The new social story book. Arlington, TX: Future Horizons; 2015.
73. Bearss K, Johnson C, Smith T, *et al*. Effect of parent training vs parent education on behavioral problems in children with autism spectrum disorder: a randomized clinical trial. JAMA. 2015;313(15):1524-33. DOI:10.1001/jama.2015.3150
74. Zwi M, Jones H, Thorgaard C, *et al*. Parent training interventions for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 years. Cochrane Database Syst Rev. 2011;(12):CD003018. DOI:10.1002/14651858.CD003018.pub3
75. DuPaul GJ, Weyandt LL, Janusis GM. ADHD in the classroom: Effective intervention strategies. Theory Pract. 2011;50(1):35-42. DOI:10.1080/00405841.2011.534935
76. Laugeson EA, Frankel F. Social skills for teenagers with developmental and autism spectrum disorders: The PEERS treatment manual. New York, NY: Routledge; 2010.
77. Scarpa A, Reyes NM. Improving emotion regulation with CBT in young children with high functioning autism spectrum disorders: a pilot study. Behav Cogn Psychother. 2011;39(4):495-500. DOI:10.1017/S1352465811000063
78. Cortese S, Adamo N, Del Giovane C, *et al*. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727-38. DOI:10.1016/S2215-0366(18)30269-4
79. Reichow B, Volkmar FR, Bloch MH. Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/hyperactivity disorder in children with pervasive developmental disorders. J Autism Dev Disord. 2013;43(10):2435-41. DOI:10.1007/s10803-013-1793-z
80. Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005;62(11):1266-74. DOI:10.1001/archpsyc.62.11.1266
81. Jahromi LB, Kasari CL, McCracken JT, *et al*. Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. J Autism Dev Disord. 2009;39(3):395-404. DOI:10.1007/s10803-008-0636-9
82. Harfterkamp M, van de Loo-Neus G, Minderaa RB, *et al*. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(7):733-41. DOI:10.1016/j.jaac.2012.04.011
83. Scahill L, McCracken JT, King BH, *et al*. Extended-Release Guanfacine for Hyperactivity in Children with Autism Spectrum Disorder. Am J Psychiatry. 2015;172(12):1197-206. DOI:10.1176/appi.ajp.2015.15010055
84. Marcus RN, Owen R, Kamen L, *et al*. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(11):1110-9. DOI:10.1097/CHI.0b013e3181b76658
85. Williams K, Brignell A, Randall M, *et al*. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2013;(8):CD004677. DOI:10.1002/14651858.CD004677.pub3
86. Chiang HL, Gau SS. Comorbid psychiatric conditions as mediators to predict later social adjustment in youths with autism spectrum disorder. J Child Psychol Psychiatry. 2016;57(1):103-11. DOI:10.1111/jcpp.12450
87. Hummelen B, Pedersen G, Wilberg T, *et al*. Poor peer functioning in girls with ADHD and ASD: A comparative study. Res Dev Disabil. 2019;94:103477. DOI:10.1016/j.ridd.2019.103477
88. Joshi G, Wozniak J, Petty C, *et al*. Psychiatric comorbidity and functioning in a clinically referred population of adults with autism spectrum disorders: a comparative study. J Autism Dev Disord. 2013;43(6):1314-25. DOI:10.1007/s10803-012-1679-5
89. Howlin P, Moss P. Adults with autism spectrum disorders. Can J Psychiatry. 2012;57(5):275-83. DOI:10.1177/070674371205700502
90. Eaves LC, Ho HH. Young adult outcome of autism spectrum disorders. J Autism Dev Disord. 2008;38(4):739-47. DOI:10.1007/s10803-007-0441-x
91. Helles A, Gillberg IC, Gillberg C, Billstedt E. Asperger syndrome in males over two decades: quality of life in relation to diagnostic stability and psychiatric comorbidity. Autism. 2017;21(4):458-69. DOI:10.1177/1362361316650090
92. Rydzewska E, Hughes-McCormack LA, Gillberg C, *et al*. Prevalence of sensory impairments, physical and intellectual disabilities, and mental health in children

and young people with self/proxy-reported autism: observational study of a whole country population. Autism. 2019;23(5):1201-9. DOI:10.1177/1362361318791279
93. Insel T, Cuthbert B, Garvey M, *et al*. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167(7):748-51. DOI:10.1176/appi.ajp.2010.09091379
94. Turygin N, Matson JL, MacMillan K, Konst M. The relationship between attention deficit/hyperactivity disorder symptoms in children with autism spectrum disorder and symptoms of severity. Dev Neurorehabil. 2013;16(2):108-14. DOI:10.3109/17518423.2012.741147
95. Havdahl KA, Hus Bal V, Huerta M, *et al*. Multidimensional influences on autism symptom measures: implications for use in etiological research. J Am Acad Child Adolesc Psychiatry. 2016;55(12):1054-1063.e3. DOI:10.1016/j.jaac.2016.09.490
96. Dworzynski K, Ronald A, Bolton P, Happé F. How different are girls and boys above and below the diagnostic threshold for autism spectrum disorders? J Am Acad Child Adolesc Psychiatry. 2012;51(8):788-97. DOI:10.1016/j.jaac.2012.05.018
97. Cortese S, Holtmann M, Banaschewski T, *et al*. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry. 2013;54(3):227-46. DOI:10.1111/jcpp.12036
98. Di Martino A, Fair DA, Kelly C, *et al*. Unraveling the miswired connectome: a developmental perspective. Neuron. 2014;83(6):1335-53. DOI:10.1016/j.neuron.2014.08.050

How to Cite This Article
Hassan S. A comprehensive narrative review of the comorbidity of autism spectrum disorder and ADHD in children. International Journal of Pediatrics and Neonatology. 2026;8(1):25-39.